Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F Mohr

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 9, 2008
Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infectionsJohn F Mohr
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 23, 2007
Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureusJohn F Mohr, Barbara E Murray
Expert Review of Anti-Infective Therapy|March 18, 2017
The antibiotic pipeline: reviving research and development and speeding drugs to marketKatherine H Luepke, John F Mohr
Drug Safety|March 28, 2008
Dysglycaemias and fluoroquinolonesRoshan J Lewis, John F Mohr
Diagnostic Microbiology and Infectious Disease|February 20, 2004
Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patientsJohn F Mohr, Audrey Wanger, John H Rex
The Journal of Antimicrobial Chemotherapy|October 15, 2009
Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studiesJudith N Steenbergen, John F Mohr, Grace M Thorne
Expert Review of Anti-Infective Therapy|September 14, 2017
Intravenous fosfomycin for the treatment of hospitalized patients with serious infectionsAndrew F Shorr, Jason M Pogue, John F Mohr
The Journal of Antimicrobial Chemotherapy|January 14, 2015
Comment on: Efficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trialsMichele H Potashman, Danielle N Formella, Kamal Hamed, et al.
International Journal of Antimicrobial Agents|February 10, 2009
Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE)John F Mohr, Lawrence V Friedrich, Sara Yankelev, et al.
Pharmacotherapy|October 28, 2009
Antimicrobial susceptibility testing: a primer for cliniciansKristi M Kuper, Deborah M Boles, John F Mohr, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 9, 2008
Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infectionsJohn F Mohr
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 23, 2007
Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureusJohn F Mohr, Barbara E Murray
Expert Review of Anti-Infective Therapy|March 18, 2017
The antibiotic pipeline: reviving research and development and speeding drugs to marketKatherine H Luepke, John F Mohr
Drug Safety|March 28, 2008
Dysglycaemias and fluoroquinolonesRoshan J Lewis, John F Mohr
Diagnostic Microbiology and Infectious Disease|February 20, 2004
Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patientsJohn F Mohr, Audrey Wanger, John H Rex
The Journal of Antimicrobial Chemotherapy|October 15, 2009
Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studiesJudith N Steenbergen, John F Mohr, Grace M Thorne
Expert Review of Anti-Infective Therapy|September 14, 2017
Intravenous fosfomycin for the treatment of hospitalized patients with serious infectionsAndrew F Shorr, Jason M Pogue, John F Mohr
The Journal of Antimicrobial Chemotherapy|January 14, 2015
Comment on: Efficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trialsMichele H Potashman, Danielle N Formella, Kamal Hamed, et al.
International Journal of Antimicrobial Agents|February 10, 2009
Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE)John F Mohr, Lawrence V Friedrich, Sara Yankelev, et al.
Pharmacotherapy|October 28, 2009
Antimicrobial susceptibility testing: a primer for cliniciansKristi M Kuper, Deborah M Boles, John F Mohr, et al.
Pageof 4